| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/04/2001 | WO2001000644A1 Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses |
| 01/04/2001 | WO2001000638A2 Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses |
| 01/04/2001 | WO2001000622A1 Prodrugs of carbamate inhibitors of impdh |
| 01/04/2001 | WO2001000306A1 Preparation of a therapeutic composition |
| 01/04/2001 | WO2001000247A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | WO2001000246A2 Hydrogels derived from chitosan and poly(ethylene glycol) |
| 01/04/2001 | WO2001000242A2 Polycation-based bioconjugates |
| 01/04/2001 | WO2001000235A1 Prion protein binding proteins and uses thereof |
| 01/04/2001 | WO2001000230A1 Drug composition containing lecithin-modified superoxide dismutase |
| 01/04/2001 | WO2001000229A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | WO2001000228A1 Method for preventing tumoral growth |
| 01/04/2001 | WO2001000227A1 Gonadotropin releasing hormone antagonist |
| 01/04/2001 | WO2001000226A1 Ophthalmic ointments for treating infective eye diseases |
| 01/04/2001 | WO2001000225A1 Hla binding peptides and their uses |
| 01/04/2001 | WO2001000224A1 Compositions and methods for treatment of sexual dysfunction |
| 01/04/2001 | WO2001000223A2 Multiple agent diabetes therapy |
| 01/04/2001 | WO2001000222A1 Anti-depressant effects of corticotropin release inhibiting factor |
| 01/04/2001 | WO2001000221A2 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | WO2001000220A2 Lipoprotein lipase (lpl) variant therapeutics |
| 01/04/2001 | WO2001000214A1 Src kinase inhibitor compounds |
| 01/04/2001 | WO2001000210A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | WO2001000198A2 Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| 01/04/2001 | WO2000064400A3 Methods for treating congestive heart failure |
| 01/04/2001 | WO2000063237A3 Pseudomycin analogs |
| 01/04/2001 | WO2000062798A3 Angiogenic growth factors for treatment of peripheral neuropathy |
| 01/04/2001 | WO2000061069A3 Methods and compositions for use in the treatment of hyperlipidemia |
| 01/04/2001 | WO2000060082A3 Vesicle associated proteins |
| 01/04/2001 | WO2000057921A3 Peroral gene therapy of diabetes and obesity |
| 01/04/2001 | WO2000056405A3 Human tumor necrosis factor receptor-like 2 |
| 01/04/2001 | WO2000054797A3 Pharmaceutical compositions comprising tgf-beta |
| 01/04/2001 | WO2000053236A3 Methods and compositions for targeted drug delivery |
| 01/04/2001 | WO2000049145A3 Hematopoietic genes hzf and hhl and polypeptides encoded thereof |
| 01/04/2001 | WO2000047235A3 Methods of stimulating angiogenesis |
| 01/04/2001 | WO2000039302A3 Improved expression of hiv polypeptides and production of virus-like particles |
| 01/04/2001 | WO2000038715A3 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 01/04/2001 | WO2000029438A9 Egf-like nucleic acids and polypeptides and uses thereof |
| 01/04/2001 | WO2000026251A9 A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX |
| 01/04/2001 | WO2000012690A9 Laminin 5 for treatment of bone defects |
| 01/04/2001 | CA2415095A1 Secreted alpha-helical protein-36 |
| 01/04/2001 | CA2380873A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | CA2378227A1 Antisense modulation of pi3k p85 expression |
| 01/04/2001 | CA2377752A1 Methods and compositions relating to pancreatic islet and .beta.-cell dysfunction |
| 01/04/2001 | CA2377721A1 Sgip peptides |
| 01/04/2001 | CA2377585A1 Methods for making apo-2 ligand using divalent metal ions |
| 01/04/2001 | CA2377513A1 Hetero-associating coiled-coil peptides |
| 01/04/2001 | CA2377489A1 Chimeric proteins mediating targeted apoptosis |
| 01/04/2001 | CA2377437A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | CA2377435A1 Compositions and methods for forming and strengthening bone |
| 01/04/2001 | CA2377433A1 Compound derived from an offset orf of the ice gene |
| 01/04/2001 | CA2377273A1 Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof |
| 01/04/2001 | CA2377265A1 Somatostatin agonists |
| 01/04/2001 | CA2377229A1 Self-aligning peptides derived from human elastin and other fibrous proteins |
| 01/04/2001 | CA2377224A1 Inhibitors of the integrin .alpha.v.beta.6 |
| 01/04/2001 | CA2377211A1 Copolymers for transporting nucleic acids in the cell |
| 01/04/2001 | CA2377204A1 Purification and stabilization of peptide and protein pharmaceutical agents |
| 01/04/2001 | CA2377074A1 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body |
| 01/04/2001 | CA2376951A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376935A1 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | CA2376931A1 Preparation of a therapeutic composition |
| 01/04/2001 | CA2376920A1 Method for preventing tumoral growth |
| 01/04/2001 | CA2376914A1 Prion protein binding proteins and uses thereof |
| 01/04/2001 | CA2376912A1 Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| 01/04/2001 | CA2376859A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | CA2376714A1 Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers |
| 01/04/2001 | CA2375952A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | CA2374610A1 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | CA2372696A1 Novel protein and dna thereof |
| 01/04/2001 | CA2370887A1 Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria |
| 01/04/2001 | CA2370568A1 Tankyrase2 materials and methods |
| 01/04/2001 | CA2370413A1 Hla binding peptides and their uses |
| 01/04/2001 | CA2370099A1 Bh3 modified peptides |
| 01/04/2001 | CA2370081A1 Lpl variant therapeutics |
| 01/04/2001 | CA2369839A1 Compositions of insulin and insulin-related peptide for treating diabetes |
| 01/04/2001 | CA2369145A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | CA2368098A1 Complementary dna's encoding proteins with signal peptides |
| 01/04/2001 | CA2365341A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/04/2001 | CA2341974A1 Gonadotropin releasing hormone antagonist |
| 01/03/2001 | EP1065270A1 HUMAN p51 GENES AND GENE PRODUCTS THEREOF |
| 01/03/2001 | EP1065269A1 Genomic gene encoding hm1.24 antigen protein and promoter thereof |
| 01/03/2001 | EP1065215A1 Homomeric and heteromeric AMPA receptors |
| 01/03/2001 | EP1065214A1 Novel physiologically active peptides and utilization thereof |
| 01/03/2001 | EP1065213A2 HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
| 01/03/2001 | EP1065212A2 Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines |
| 01/03/2001 | EP1064952A2 Methods and compositions for the suppression of neu mediated transformations |
| 01/03/2001 | EP1064951A2 Erythropoietin derivatives |
| 01/03/2001 | EP1064949A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064934A1 GRF-containing lyophilized pharmaceutical composition |
| 01/03/2001 | EP1064403A1 Antisense modulation of pecam-1 |
| 01/03/2001 | EP1064402A1 Antisense modulation of lfa-3 |
| 01/03/2001 | EP1064395A1 Novel molecules of the g protein-coupled heptahelical receptor superfamily and uses therefor |
| 01/03/2001 | EP1064391A1 Antisense modulation of human mdm2 expression |
| 01/03/2001 | EP1064388A1 Human casb12 polypeptide, a serine protease |
| 01/03/2001 | EP1064383A2 Interferon alpha plasmids and delivery systems, and methods of making and using the same |
| 01/03/2001 | EP1064382A2 Polypeptides homologous to vegf and bmp1 |
| 01/03/2001 | EP1064380A1 EXPRESSION OF THE $i(INSL4) GENE IN HUMAN EMBRYONIC BONE TISSUES AND APPLICATIONS |
| 01/03/2001 | EP1064379A2 Human nucleic acid sequences from tissue of breast tumors |
| 01/03/2001 | EP1064377A1 Casb414: antigen overexpressed in several tumours |
| 01/03/2001 | EP1064375A2 Human calcium-binding proteins |
| 01/03/2001 | EP1064374A1 Novel molecules expressed during muscle development and genetic sequences encoding the same |
| 01/03/2001 | EP1064372A2 Compounds and methods for therapy and diagnosis of lung cancer |